Karyopharm Therapeutics Stock Earnings Reports

Karyopharm reported Q1 2026 results and highlighted several near-term value drivers. The Phase III SENTRY myelofibrosis trial showed a strong spleen volume reduction (SVR35 50% vs 28% at week 24), a promising overall survival signal (OS HR 0.43, nominal p=0.0222) and evidence of variant allele frequency reductions that suggest potential disease modification; data will be presented as a late-breaking oral at ASCO and the company plans regulatory engagement with the FDA. Enrollment in the Phase III EXPORT-EC042 endometrial cancer trial is complete (257 ITT; ~220 MITT) with topline results expected mid-2026; the program targets p53 wild-type, MMR-proficient patients where unmet need is high. Commercially, management believes it can leverage an existing sales organization focused on community accounts for rapid uptake in both indications and estimates up to ~$1 billion peak U.S. revenue potential in myelofibrosis. Financials: Q1 total revenue $35.1M, U.S. XPOVIO net product revenue $29.2M, R&D $33.8M, SG&A $26.7M, net loss $22.4M; cash, cash equivalents and restricted cash $91.2M (including ~ $50M financing in March) with runway into late Q3 2026 under current plan. Guidance was reaffirmed: total revenue $130–150M and U.S. XPOVIO net product revenue $115–130M for 2026; combined R&D and SG&A $230–245M. Management emphasized dose and supportive-care optimizations to improve tolerability and on-going efforts to engage regulators, publish data, and prepare for potential launches.